HealthDay News — During the week of January 26 through February 1, 2025, flu activity remained elevated in the US, with 43 states reporting high or very high outpatient respiratory illness activity, ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

The phase 2 CAFETERIA study included participants aged 4 to 14 years who were able to tolerate at least 143mg of peanut protein.

Two studies show endovascular thrombectomy does not lead to better outcomes at 90 days or result in lower incidence of death ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

Opioid prescriptions in the emergency department linked to small increases in hospital admission and subsequent opioid prescription use ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with ...

Three recommendations suggest monotherapy options for preventing episodic migraine headache in outpatient settings ...

The NIH said capping indirect cost payments will save billions of dollars. Universities said it will disrupt vital, life-saving research.

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

“Results of this cluster trial demonstrate that salt substitution was safe, along with reduced risks of stroke recurrence and death, which underscores large health gains from scaling up this low-cost ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.